Biomarkers in osteoarthritis

Kraus, Virginia B.

doi:10.1097/01.bor.0000174195.15421.17

Cited by 40 publications

(22 citation statements)

References 32 publications

(4 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several such molecular markers are currently being investigated. [1][2][3][4] The advantage of this approach is the potential for detecting pathological changes early in the disease course, facilitating early intervention. Furthermore, effects of treatment may be discerned by repeated measurements of such markers-for example, COMP-and these effects seem not to be directly linked to inflammation.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Diurnal variation in serum levels of cartilage oligomeric matrix protein in patients with knee osteoarthritis or rheumatoid arthritis

Andersson

Petersson

Karlsson

et al. 2006

Annals of the Rheumatic Diseases

View full text Add to dashboard Cite

Objective: To monitor changes in serum concentrations of cartilage oligomeric matrix protein (COMP) during a 24-h period to determine any diurnal variation, and to estimate the half life of COMP in the circulation in patients with symptomatic knee osteoarthritis and in those with rheumatoid arthritis. Methods: Serum samples were drawn every 4 h (7 samples/patient over 24 h) in 10 patients with knee osteoarthritis and 14 patients with rheumatoid arthritis. Osteoarthritis was defined radiographically and clinically (American College of Rheumatology (ACR) criteria) and rheumatoid arthritis according to the 1987 ACR criteria. Serum COMP was measured by sandwich ELISA. A statistical model for the diurnal variation in the COMP levels was developed using the computer program NONMEM. Results: No considerable changes in COMP levels were observed during the day between 08:00 and 21:00 in either group. A significant decrease in serum COMP was apparent during bed rest at night, reaching the lowest levels between 04:00 and 05:00 (p,0.03 or better v all other time points) in patients with osteoarthritis and in those with rheumatoid arthritis. From the rate of decreasing serum COMP levels, a putative half life of COMP in the circulation was estimated to be 7.4 h. Conclusion: During normal daytime activities, serum COMP levels are constant. The decrease during the night indicates a rapid elimination of COMP once it has reached the circulation. The stable COMP levels during the day suggest that it is not necessary to further standardise the time of serum sampling in clinical practice.

show abstract

Section: Discussionmentioning

confidence: 99%

“…4 One such biomarker is cartilage oligomeric matrix protein (COMP). COMP is a 435-KDa non-collagenous protein composed of five subunits primarily identified in cartilage.…”

mentioning

confidence: 99%

Diurnal variation in serum levels of cartilage oligomeric matrix protein in patients with knee osteoarthritis or rheumatoid arthritis

Andersson

Petersson

Karlsson

et al. 2006

Annals of the Rheumatic Diseases

View full text Add to dashboard Cite

show abstract

“…In connection with the possible symptomatic efficacy, glucosamine and chondroitin sulfate have been reported to reduce the osteoarthritic joint damage and to slow the progression of OA (13,14,48). Recently, various biomarkers have been developed to detect the articular alterations in OA (49,50), and there are accumulating data supporting the association of the changes in various CII degradation biomarkers, such as CTX-II, C1, 2C and C2C (51)(52)(53), and a synovial inflammation biomarker HA (54,55) with the disease progression in knee OA. In the present study, we utilized C2C and HA for evaluating the effects of the test supplement on the pathophysiological changes in the cartilage and synovium, respectively, as described previously (56).…”

Section: Discussionmentioning

confidence: 99%

Effect of a glucosamine-based combination supplement containing chondroitin sulfate and antioxidant micronutrients in subjects with symptomatic knee osteoarthritis: A pilot study

Nakasone¹,

Watabe²,

Watanabe³

et al. 2011

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. In the present study, we aimed to investigate the potential effect of a glucosamine (1,200 mg/day)-based dietary supplement combined with chondroitin sulfate and three antioxidant micronutrients, namely methylsulfonylmethane, guava leaf extract, and vitamin D (test supplement) on osteoarthritis (OA) of the knee. A 16-week, randomized, double-blinded, placebo-controlled trial was conducted involving 32 subjects with symptomatic knee OA. Clinical outcomes were measured using the Japanese Knee Osteoarthritis Measure (JKOM) for symptoms and a study diary-based visual analog scale (diary VAS) for pain at baseline and at weeks 4, 8, 12 and 16 during the 16-week intervention period. Furthermore, biomarkers for cartilage type II collagen degradation (C2C) and synovitis hyaluronan (HA) were measured. As compared with the baseline, the JKOM pain subscale was significantly improved at all of the four assessment time points in the test group, but was not at any time point in the placebo group. On the other hand, all of the four symptom subscales and the aggregated total symptoms were significantly improved in the two groups at one or more time points. However, all of these clinical improvements were greater in extent in the test group than in the placebo group, and there were significant differences between groups in the magnitude of changes from baseline for one subscale 'general activities' and the aggregated total symptoms at week 8 (P<0.05). The results of efficacy assessments with the diary VAS showed that all of the three pain subscales were significantly improved only in the test group at almost all the time points. Moreover, serum levels of C2C and HA were decreased by 10 and 25%, respectively, at week 16 in the test group, albeit not statistically significant, without any detectable changes in the placebo group. In conclusion, although the results obtained in this study were not conclusive, the tested glucosamine-based combination supplement is likely to have a beneficial effect on pain and other symptoms associated with knee OA.

show abstract

“…Biomarker discovery and validation for OA has accelerated significantly as we have increased our understanding of the anatomy, physiology, biochemistry and cell biology of joint tissues and their molecular complexity (141). One of the main issues responsible for driving this agenda has been the acute need for improved OA outcome measures in clinical trials (141,142).…”

Section: Oa Biomarkers: Discovery Validation and Commercializationmentioning

confidence: 99%

Applications of proteomics in cartilage biology and osteoarthritis research

Williams¹,

Smith²,

Allaway³

et al. 2011

Front Biosci

View full text Add to dashboard Cite

In osteoarthritis (OA) the turnover of extracellular matrix (ECM) macromolecules is disrupted by catabolic changes that lead to the production of a range of inflammatory mediators and the loss and fragmentation of proteoglycans, fibrillar and non-fibrillar collagens. These events result in the degradation and release of ECM fragments, which are potential biomarkers that can be detected in synovial fluid, blood and urine. Proteomics is increasingly applied in cartilage research and has the potential to advance our understanding of the biology of this tissue. It can also provide mechanistic insight into disease pathogenesis and progression and facilitate biomarker discovery. Here we review the area of cartilage and chondrocyte proteomics and published studies relevant to arthritis and OA biomarkers, highlighting areas of current and future research and development. Markers of tissue turnover in joints have the capacity to reflect disease-relevant biological activity potentially enabling a more rational approach to healthcare management. Therefore proteomic studies of cartilage, chondrocytes and their subcellular fractions and other joint cells and tissues may be particularly relevant in diagnostic orthopedics and therapeutic research.

show abstract

Biomarkers in osteoarthritis

Cited by 40 publications

References 32 publications

Diurnal variation in serum levels of cartilage oligomeric matrix protein in patients with knee osteoarthritis or rheumatoid arthritis

Diurnal variation in serum levels of cartilage oligomeric matrix protein in patients with knee osteoarthritis or rheumatoid arthritis

Effect of a glucosamine-based combination supplement containing chondroitin sulfate and antioxidant micronutrients in subjects with symptomatic knee osteoarthritis: A pilot study

Applications of proteomics in cartilage biology and osteoarthritis research

Contact Info

Product

Resources

About